A novel mouse model of rare neurodevelopmental disorder, TBCK Syndrome
Authors:
- Ashley J. Melendez-PerezAMAshley J. Melendez-Perez
- Emily L. DurhamEDEmily L. Durham
- Dana E. Layo-CarrisDLDana E. Layo-Carris
- Elizabeth M. GonzalezEGElizabeth M. Gonzalez
- Emily E. LubinELEmily E. Lubin
- Sarina M. SmithSSSarina M. Smith
- Rajesh AngireddyRARajesh Angireddy
- Xiao-Min WangXWXiao-Min Wang
- Kelly J. AbdallaKAKelly J. Abdalla
Preprint
Abstract
TBCK Syndrome is a rare Mendelian disorder caused by variants in the TBCK gene. Although symptoms affect multiple organ systems, hallmark features include intellectual and developmental disability, craniofacial differences, hypotonia, and premature death. At the cellular level, TBCK has been implicated in mTOR signaling, autophagy, mitophagy, and mRNA trafficking; however, the mechanisms underlying disease onset and progression remain unclear. To address this gap, we characterized a mouse model of TBCK Syndrome. These mice lack exon 5 of the TBCK gene, resulting in a whole-body knockout of Tbck , modeling the most severe known variant. We performed a comprehensive battery of developmental assays, along with microcomputed tomography and histological analyses, which revealed systemic alterations consistent with those observed in affected individuals. Notably, phenotypic changes arising from Tbck loss emerge early and are detectable in the brain, indicating a primary neurodevelopmental origin of disease pathology. Rigorous characterization of this Tbck-deficient mouse establishes the first in vivo platform to investigate disease mechanisms and provides a foundation for preclinical evaluation of gene and targeted pharmacological therapy strategies. Summary Statement: This study establishes a rigorously validated animal model recapitulating systemic features of TBCK Syndrome, enabling targeted investigation of disease biology and preclinical assessment of candidate therapies.Keywords
Funding Information
- Children’s Hospital of Philadelphia Skeletal Health and Disease Research Affinity Group (7260260624-20)
- National Institute of General Medical Sciences (T32GM008638)
- TBCK Foundation
- National Human Genome Research Institute (T32HG009495)
- Eagles Autism Foundation
- NICHD (F30 F30HD112125)
- Chan Zuckerberg Initiative
- Burroughs Wellcome Fund
- Hartwell Foundation
This publication has 53 references indexed in Scilit:
- Cardiac Involvement and TBCK‐Related Neurodevelopmental Disorder: Is It a New Feature of This Condition?American Journal of Medical Genetics Part A, 2025
- Heterozygous variants in TBCK cause a mild neurologic syndrome in humans and miceAmerican Journal of Medical Genetics Part A, 2023
- Raising awareness of TBC1 domain‐containing kinase (TBCK) epileptic encephalopathy among Puerto Rican childrenAnnals of the Child Neurology Society, 2023
- A recurrent single‐exon deletion in TBCK might be under‐recognized in patients with infantile hypotonia and psychomotor delayHuman Mutation, 2022
- A novel variant of C12orf4 linked to autosomal recessive intellectual disability type 66 with phenotype expansionThe Journal of Gene Medicine, 2021
- PPP1R21‐related syndromic intellectual disability: Report of an adult patient and reviewAmerican Journal of Medical Genetics Part A, 2020
- Phosphotungstic acid‐enhanced microCT: Optimized protocols for embryonic and early postnatal miceDevelopmental Dynamics, 2019
- Biallelic loss of function variants in PPP1R21 cause a neurodevelopmental syndrome with impaired endocytic functionHuman Mutation, 2018
- Homozygous boricua TBCK mutation causes neurodegeneration and aberrant autophagyAnnals of Neurology, 2017
- TBCK‐related intellectual disability syndrome: Case study of two patientsAmerican Journal of Medical Genetics Part A, 2016